Peptides Similar to GUBamy
Compare GUBamy with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Pramlintide: High - Both are amylin receptor agonists. Pramlintide is the only approved amylin analog. GUBamy additionally activates calcitonin receptors (DACRA) and has a dramatically longer half-life.
- •Cagrilintide: High - Both are long-acting amylin analogs with weekly dosing. Both target obesity. Cagrilintide is AMY-selective; GUBamy is a DACRA (also activates calcitonin receptors).
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| GUBamy (current) | - | - |
| Pramlintide | High - Both are amylin receptor agonists. Pramlintide is the only approved amylin analog. GUBamy additionally activates calcitonin receptors (DACRA) and has a dramatically longer half-life. | Pramlintide requires thrice-daily injection (48-min half-life) vs weekly for GUBamy (11-day half-life). Pramlintide is AMY-selective; GUBamy is a DACRA. Pramlintide is approved for diabetes adjunct; GUBamy targets obesity. |
| Cagrilintide | High - Both are long-acting amylin analogs with weekly dosing. Both target obesity. Cagrilintide is AMY-selective; GUBamy is a DACRA (also activates calcitonin receptors). | Cagrilintide is being developed primarily as combination therapy with semaglutide (CagriSema). GUBamy has DACRA activity while cagrilintide is AMY-selective. Different development partners (Novo Nordisk vs AbbVie). |
| Petrelintide | High - Both are next-generation long-acting amylin analogs targeting obesity. Both aim to provide meaningful weight loss through amylin-pathway activation with convenient dosing. | GUBamy is a DACRA (dual amylin + calcitonin); petrelintide receptor selectivity profile may differ. Different developers (Gubra/AbbVie vs Zealand Pharma). Different stages of development. |
PramlintideHigh - Both are amylin receptor agonists. Pramlintide is the only approved amylin analog. GUBamy additionally activates calcitonin receptors (DACRA) and has a dramatically longer half-life.
Differences
Pramlintide requires thrice-daily injection (48-min half-life) vs weekly for GUBamy (11-day half-life). Pramlintide is AMY-selective; GUBamy is a DACRA. Pramlintide is approved for diabetes adjunct; GUBamy targets obesity.
Advantages
Once-weekly dosing vs thrice-daily. Dual receptor activation may provide superior weight loss. Greater weight loss potential (7.77% at day 43 in phase 1).
Disadvantages
Phase 1 only (pramlintide is FDA-approved). Extremely limited safety data. No diabetes indication data. Not yet commercially available.
CagrilintideHigh - Both are long-acting amylin analogs with weekly dosing. Both target obesity. Cagrilintide is AMY-selective; GUBamy is a DACRA (also activates calcitonin receptors).
Differences
Cagrilintide is being developed primarily as combination therapy with semaglutide (CagriSema). GUBamy has DACRA activity while cagrilintide is AMY-selective. Different development partners (Novo Nordisk vs AbbVie).
Advantages
DACRA mechanism may provide additional metabolic benefits beyond AMY-selective agonism. Longer half-life (11 days vs 7 days).
Disadvantages
Much earlier in development (phase 1 vs phase 3 for CagriSema). No combination data with GLP-1 RAs yet. Less clinical experience.
PetrelintideHigh - Both are next-generation long-acting amylin analogs targeting obesity. Both aim to provide meaningful weight loss through amylin-pathway activation with convenient dosing.
Differences
GUBamy is a DACRA (dual amylin + calcitonin); petrelintide receptor selectivity profile may differ. Different developers (Gubra/AbbVie vs Zealand Pharma). Different stages of development.
Advantages
AbbVie partnership provides substantial development resources. Phase 1 weight loss data (7.77% at day 43) is promising.
Disadvantages
Both are early-stage with limited clinical data. Direct comparison is not possible at this stage.
Peptides Related to GUBamy#
GUBamy is part of the emerging amylin-class therapeutic landscape for obesity. The amylin pathway has gained significant pharmaceutical interest as a complement to GLP-1 receptor agonism, with multiple companies developing long-acting amylin analogs. GUBamy is distinguished as a DACRA (dual amylin and calcitonin receptor agonist) rather than an AMY-selective agent.
Pramlintide (Symlin)#
Pramlintide is the only FDA-approved amylin analog and the foundational reference for the amylin class. Approved in 2005 as an adjunct to insulin for type 1 and type 2 diabetes, it demonstrates the therapeutic potential of amylin agonism but is limited by its short half-life.
Mechanism comparison: Both activate amylin receptors to reduce appetite and delay gastric emptying. Pramlintide is primarily AMY-selective, while GUBamy additionally activates calcitonin receptors. This dual receptor activation (DACRA) may provide metabolic benefits beyond what AMY-selective agents achieve.
Practical comparison: The most dramatic difference is dosing convenience. Pramlintide's 48-minute half-life requires injection before each meal (3x daily), which contributed to its limited commercial adoption despite clear metabolic benefits. GUBamy's 11-day half-life enables once-weekly dosing.
| Parameter | Pramlintide | GUBamy |
|---|---|---|
| Half-life | ~48 minutes | ~11 days |
| Dosing | 3x daily (before meals) | Once weekly |
| Receptor profile | AMY-selective | DACRA (AMY + CTR) |
| Indication | Diabetes (adjunct to insulin) | Obesity (target) |
| Regulatory status | FDA-approved (2005) | Phase 1 |
| Max weight loss | ~2-3 kg (adjunct to insulin) | -7.77% at day 43 |
Cagrilintide (Novo Nordisk)#
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk, primarily as the amylin component of CagriSema (cagrilintide + semaglutide combination).
Mechanism comparison: Both are long-acting amylin analogs with weekly dosing. The key mechanistic difference is that cagrilintide is AMY-selective while GUBamy additionally activates calcitonin receptors. Whether DACRA activity provides clinically meaningful advantages over AMY-selective agonism is an open question.
Development strategy: Cagrilintide's primary value proposition is in combination with semaglutide (CagriSema), which has shown weight loss exceeding 20% in phase 3 trials. GUBamy is similarly expected to be developed in combination with GLP-1 RAs, though no clinical combination data exist yet.
Petrelintide (Zealand Pharma)#
Petrelintide is a long-acting amylin analog in development by Zealand Pharma. It is being positioned as a potential competitor to cagrilintide, with claims of better tolerability and muscle preservation properties.
Key comparison: Both GUBamy and petrelintide represent next-generation amylin analogs from Nordic biotechnology companies. Direct comparison is premature given the early stage of both programs.
Amycretin (Novo Nordisk)#
Amycretin is a single-molecule co-agonist of amylin and GLP-1 receptors. Unlike GUBamy (which would need to be combined separately with a GLP-1 RA), amycretin combines both mechanisms in one peptide.
Key trade-off: Amycretin's single-molecule approach is simpler from a development and dosing perspective, but limits the ability to independently titrate each mechanism. GUBamy as a separate molecule offers the flexibility of dose-independent combination.
Summary Comparison#
| Feature | GUBamy | Pramlintide | Cagrilintide | Petrelintide | Amycretin |
|---|---|---|---|---|---|
| Class | DACRA | AMY agonist | AMY agonist | AMY agonist | AMY + GLP-1 |
| Half-life | ~11 days | ~48 min | ~7 days | Extended | Extended |
| Dosing | QW | TID | QW | QW or less | QW |
| Phase | Phase 1 | Approved | Phase 3 (combo) | Phase 2 | Phase 1/2 |
| Developer | Gubra/AbbVie | Various | Novo Nordisk | Zealand | Novo Nordisk |
| Key differentiator | DACRA + long t1/2 | First-in-class | CagriSema combo | Muscle preservation | Single molecule |
Related Reading#
Frequently Asked Questions About GUBamy
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer